Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 12:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Systemic Diseases Clear all
Completed Phase 1 Interventional

A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases

NCT02780674
View directory record Official record
Conditions
Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc
Interventions
MEDI7734, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Anniston, Alabama • Birmingham, Alabama • Danbury, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Jun 11, 2026, 12:06 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis

NCT00042588
View directory record Official record
Conditions
Pneumonia, Sepsis
Interventions
Recombinant Chimeric Monoclonal Antibody
Drug
Lead sponsor
ICOS Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 11, 2026, 12:06 AM EDT
Completed No phase listed Observational

Serum Procalcitonin

NCT00954551
View directory record Official record
Conditions
Subarachnoid Hemorrhage (SAH)
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Jun 11, 2026, 12:06 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Recovery of Physical Function After Critical Illness In Older Adults

NCT07225257
View directory record Official record
Conditions
Sepsis, Acute Lung Injury(ALI)
Interventions
Not listed
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jun 11, 2026, 12:06 AM EDT
Completed Phase 3 Interventional Results available

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

NCT02714595
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Best Available Therapy
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Hartford, Connecticut • Newark, Delaware • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Jun 11, 2026, 12:06 AM EDT
Terminated Phase 2 Interventional Results available

A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis

NCT03738800
View directory record Official record
Conditions
Lamellar Ichthyosis
Interventions
CD5789 Cream 200 µg/g, CD5789 Cream 100 µg/g, CD5789 Cream Vehicle
Drug
Lead sponsor
Mayne Pharma International Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
San Diego, California • Aurora, Colorado • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jun 11, 2026, 12:06 AM EDT
Completed Phase 2 Interventional Results available

Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma

NCT01239394
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
Interventions
ofatumumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Jun 11, 2026, 12:06 AM EDT
Completed Phase 2 Interventional Results available

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

NCT01529112
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Lenvatinib, Lenvatinib matched placebo, BSC
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Casa Grande, Arizona • Tucson, Arizona • Gilroy, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Jun 11, 2026, 12:06 AM EDT
Recruiting No phase listed Observational

Registry for Systemic Eczema Treatments

NCT06136767
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Year to 26 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jun 11, 2026, 12:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Inflammation and Cardiovascular Health in Women

NCT04224181
View directory record Official record
Conditions
HIV/AIDS, Myocardial Infarction
Interventions
Cardiac PET, 99mTc-tilmanocept SPECT/CT, Contrast Enhanced Coronary and Aortic Computed Tomography Angiography
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 79 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Jun 11, 2026, 12:06 AM EDT
Not yet recruiting Not applicable Interventional

Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing

NCT06842030
View directory record Official record
Conditions
Personalized Medicine, Oligometastatic Disease, Feasibility
Interventions
Darwin OncoTarget and OncoTreat
Diagnostic Test
Lead sponsor
Good Samaritan Hospital Medical Center, New York
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Islip, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jun 11, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers

NCT00545987
View directory record Official record
Conditions
HIV Infections
Interventions
TriGrid™ Delivery System, conventional intramuscular injection
Device
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Jun 11, 2026, 12:06 AM EDT
Not listed No phase listed Observational

American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis

NCT01066208
View directory record Official record
Conditions
Wegener's Granulomatosis, Microscopic Polyangiitis, Churg Strauss Syndrome, Polyarteritis Nodosa, Giant Cell Arteritis, Takayasu Arteritis
Interventions
Not listed
Lead sponsor
University of Oxford
Other
Eligibility
18 Years and older
Enrollment
3,588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Jun 11, 2026, 12:06 AM EDT
Completed No phase listed Observational

Journey of Patients With Vasculitis From First Symptom to Diagnosis

NCT03410290
View directory record Official record
Conditions
Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatous Vasculitis, Temporal Arteritis, Giant Cell Arteritis, Granulomatosis With Polyangiitis, Wegener Granulomatosis, Henoch Schonlein Purpura, IgA Vasculitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Urticarial Vasculitis
Interventions
Online Questionnaire
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Jun 11, 2026, 12:06 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis

NCT03919435
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Wegener Granulomatosis
Interventions
Trimethoprim Sulfamethoxazole
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Jun 11, 2026, 12:06 AM EDT
Recruiting No phase listed Observational

VCRC Tissue Repository

NCT02967068
View directory record Official record
Conditions
Aortitis, Cutaneous Vasculitis, Eosinophilic Granulomatosis With Polyangiitis, Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Henoch-Schonlein Purpura, IgA Vasculitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Churg-Strauss Syndrome
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
6
States / cities
Boston, Massachusetts • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 11, 2026, 12:06 AM EDT
Terminated Phase 1 Interventional

Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

NCT01164917
View directory record Official record
Conditions
Cutaneous Lupus, Discoid Lupus, Lupus, Systemic Lupus Erythematosus
Interventions
AMG811, AMG811 Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Santa Monica, California • Stanford, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Jun 11, 2026, 12:06 AM EDT
Terminated No phase listed Observational Results available

Characteristics of Cord Blood Immunologic Parameters of Infants <32 Weeks Gestation

NCT00524394
View directory record Official record
Conditions
Premature Birth, Sepsis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 3 Days
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Jun 11, 2026, 12:06 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

NCT05039619
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 11, 2026, 12:06 AM EDT
Completed No phase listed Observational

A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists

NCT06322641
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD), Systemic Inflammation
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Jun 11, 2026, 12:06 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Ultraviolet Light Therapy for Systemic Lupus Erythematosus

NCT00004375
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
ultraviolet A-1 light treatment
Procedure
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
15 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1991
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 11, 2026, 12:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of Duloxetine in the Reduction of Pain in Patient With Systemic Lupus Erythematosus

NCT01269866
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Cymbalta
Drug
Lead sponsor
Dr. Jesus Gutierrez Stone
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Jun 11, 2026, 12:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer

NCT01289353
View directory record Official record
Conditions
Breast Cancer
Interventions
Carboplatin, 3D-RT or IMRT
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Jun 11, 2026, 12:06 AM EDT
Terminated Phase 3 Interventional Results available

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

NCT04158141
View directory record Official record
Conditions
Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v8, Stage IA Pleural Malignant Mesothelioma AJCC v8, Stage IB Pleural Malignant Mesothelioma AJCC v8, Stage II Pleural Malignant Mesothelioma AJCC v8, Stage IIIA Pleural Malignant Mesothelioma AJCC v8
Interventions
Carboplatin, Cisplatin, Decortication, Intensity-Modulated Radiation Therapy, Pemetrexed, Pemetrexed Disodium, Pencil beam scanning proton therapy, Pleurectomy
Drug · Procedure · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Coral Gables, Florida • Chicago, Illinois • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jun 11, 2026, 12:06 AM EDT